What Sterility Assurance Level Is Required for Parenteral Chuanxinlian Injection?

Sterile injectable solutions containing chuanxinlian veterinary API are manufactured for intramuscular administration in swine, cattle, and small ruminants. The API, standardized to total andrographolide content not less than 98.0% by high-performance liquid chromatography, is dissolved in a vehicle composed of propylene glycol 10–20% v/v, polysorbate 80 0.5–2.0% w/v, and water for injection q.s. to 100%. Sodium metabisulfite at 0.1% w/v is added as antioxidant; disodium edetate at 0.01% w/v chelates metal ions that catalyze oxidative lactone ring opening. The solution is adjusted to pH 6.0–6.8 with citrate-phosphate buffer because andrographolide undergoes base-catalyzed hydrolysis of the γ-lactone ring above pH 7.5, and acid-catalyzed dehydration below pH 4.0. Terminal sterilization is performed in a rotary autoclave with a validated F0 value of ≥ 8.0 minutes and a chamber temperature of 121°C for 15 min; process validation must demonstrate a sterility assurance level of ≤ 10⁻⁶. The vial filling line operates in a Grade A laminar airflow zone within a Grade B cleanroom per ISO 14644-1:2015; depyrogenation of borosilicate Type I glass vials occurs in a tunnel at 250°C for ≥ 45 min. Filter integrity testing with a 0.22 µm PVDF membrane is performed before and after aseptic filling using bubble point methodology. Compatibility with silicone tubing and stainless steel 316L product contact surfaces is verified because polysorbate 80 can extract plasticizers from non-validated elastomers. The finished injection is packaged in 10 mL or 20 mL amber ampoules; light protection is mandatory because andrographolide is photosensitive in aqueous solution. Published data for this specific configuration with UV exposure limits is limited, so forced degradation under VICH GL5 photostability conditions is required to establish a shelf-life specification. Sterility is confirmed according to USP <71> and bacterial endotoxin is controlled to <0.50 EU/mg of API according to USP <85>. Residual solvent limits follow VICH GL18: propylene glycol is not classified as a Class 1 or Class 2 residual solvent, but batch records must document that the total daily exposure does not exceed 25 mg/kg body weight for the target species.

In poultry production, administration of chuanxinlian API via drinking water requires conversion of the poorly water-soluble andrographolide fraction into a rapidly dispersible solid dosage form that maintains solubility across water hardness ranges from 50 ppm to 500 ppm CaCO₃ equivalent. The water-soluble powder is prepared by micronizing the API to a D90 particle size of ≤ 25 µm using an air-jet mill, then blending with a carrier system of anhydrous lactose 60–70% w/w, povidone K30 5–8% w/w, and poloxamer 188 5–10% w/w in a ribbon blender at 12 rpm for 20 min. Sodium citrate dihydrate 2–4% w/w is incorporated as a buffering and dispersing agent; the final bulk powder is sieved through a 60-mesh (250 µm) stainless steel screen before filling into laminated foil pouches. Dissolution testing per USP <711> Apparatus II at 50 rpm, 37°C, in 900 mL of pH 6.8 phosphate buffer requires not less than 80% of labeled andrographolide to be released within 30 min. Batch-to-batch variance in wetting behavior is monitored by measuring the contact angle of a 1% w/v solution on a pressed film; values above 60° indicate incomplete dispersion and require re-milling, though published data for this specific API may vary by particle morphology. The powder is administered at a target dose of 1–2 mg andrographolide per kg body weight per day, diluted in drinking water at 0.5–1.0 g/L, for 5–7 days; consumption patterns must be validated for each flock because andrographolide bitterness reduces voluntary intake at concentrations above 1.5 g/L. Stability-indicating HPLC per USP <621> shows no more than 5% degradation after 24 months at 25°C/60% RH when the moisture content is maintained below 5.0% by loss-on-drying.

When Chuanxinlian Is Blended into Medicated Premix for Swine and Poultry

Feed premix dosage forms carry the highest mechanical stress on API stability because the active constituent is distributed through a matrix of corn cob meal, rice hull powder, and calcium carbonate that can reach 70–90% w/w of the formulation. The API is first pre-blended with hydrophilic fumed silica 2–5% w/w as a flow aid and to prevent segregation due to density differences between the API (bulk density 0.35–0.45 g/cm³) and the mineral carrier (bulk density 0.80–1.10 g/cm³). A double-screw mixer operating at 25 rpm for 15 min yields a homogeneity of ≤ 5.0% coefficient of variation measured by split sampling at 10 points across the batch. The premix is diluted into complete feed at a rate of 2–5 kg/tonne to deliver a final concentration of 40–100 mg API per kg feed, depending on target species. Critical process limits derive from heat generation during mixing: external jacket temperature must remain below 40°C because andrographolide begins to soften and adsorb irreversibly onto mineral carriers above this threshold, reducing in-feed extractability. Medicated feed production follows Regulation (EU) 2019/4 on the manufacture, placing on the market and use of medicated feed, including carry-over limits for subsequent clean feed batches not exceeding 1% of the previous medicated batch. Analytical verification uses liquid chromatography-tandem mass spectrometry with a method limit of quantification of 0.5 mg/kg feed; recovery from spiked feed matrices is 92–105% across corn, soybean, and wheat basal diets.

Compression of chuanxinlian extract into veterinary tablet matrices introduces measurable constraints related to hygroscopicity and compressibility. The API, when granulated with microcrystalline cellulose PH102 20–30% w/w, lactose monohydrate 30–40% w/w, and crospovidone 3–5% w/w, produces granules with a Carr’s index of 18–22% and Hausner ratio 1.15–1.25. Dry granulation by roller compaction at roller pressure 40–60 bar and gap width 1.5–2.0 mm is preferred over wet granulation because the API undergoes partial hydrolysis when exposed to aqueous binder solutions for more than 30 min at granulation temperatures above 30°C. Tableting is performed on a rotary press with a pre-compression force of 2–4 kN and main compression force of 8–12 kN, producing tablets with hardness 60–80 N, friability ≤ 1.0% per USP <1216>, and disintegration time ≤ 15 min in 900 mL water at 37°C per USP <701>. Dissolution testing per USP <711> Apparatus I at 100 rpm in 0.1 M hydrochloric acid shows not less than 75% release within 45 min. The tablet core is film-coated with hydroxypropyl methylcellulose 5–8% weight gain using a perforated pan coater at inlet air temperature 55–65°C; this coating masks the bitter taste and provides a moisture barrier because unprotected tablets absorb 3–5% moisture within 24 h at 40°C/75% RH. For capsules, the granulate is filled into size 0 gelatin capsules at target fill weight 350–400 mg with a tamping pin station density 0.75–0.85 g/mL; microbial limits follow USP <2021> and USP <2022> for total aerobic microbial count ≤ 10³ CFU/g.

Oral Drench Solutions for Ruminant Fever and Diarrheal Support

Oral liquid dosage forms for cattle, sheep, and goats use a non-sterile aqueous or hydroalcoholic vehicle that maintains andrographolide in solution at ambient temperatures between 10°C and 30°C without crystallization. A typical oral drench contains API sufficient to provide 10–20 mg/mL andrographolide, ethanol 10–15% v/v, propylene glycol 10–20% v/v, and purified water; ethanol content above 15% is avoided in lactating cattle due to milk residue concerns. The pH is adjusted to 6.5–7.5 with trisodium citrate; below pH 6.0 the API precipitates within 48 h, while above pH 8.0 the lactone ring undergoes first-order degradation, but published data for this specific configuration is limited, so stability-indicating HPLC per USP <621> is required for each formulation. The solution is homogenized at 3000 rpm for 15 min and passed through a 10 µm polypropylene depth filter to remove residual plant particulates. Packaging in high-density polyethylene bottles with induction-sealed foil liners is required because oxygen transmission through low-density polyethylene can accelerate oxidative degradation of the API. The drench is administered orally at a volume of 0.5–1.0 mL/kg body weight once or twice daily for 3–5 days; published data for this specific configuration in lactating dairy cows is limited, so milk withdrawal intervals are established on a case-by-case basis per regulatory review.

For neonatal calves and lambs where drenching is impractical, the chuanxinlian API is formulated as a dispersible granule that is reconstituted with milk replacer or warm water immediately before administration. The granule matrix combines sucrose 40–50% w/w, mannitol 20–30% w/w, xanthan gum 0.5–1.0% w/w, and sodium bicarbonate 2–3% w/w; the bicarbonate generates effervescent dispersion and masks the bitter API when the granule is added to 200 mL of liquid at 35–40°C. Granulation is performed in a top-spray fluidized bed at inlet air temperature 50–60°C, spray rate 8–12 g/min, and atomizing pressure 1.5–2.0 bar; the process yields granules with D50 150–250 µm and moisture content ≤ 3.0%. Dissolution testing per USP <711> Apparatus III at 10 dips/min in 900 mL pH 6.8 buffer shows not less than 80% release within 15 min. Microbial quality follows USP <2021> with total aerobic microbial count ≤ 10³ CFU/g and absence of Escherichia coli in 1 g. Storage in aluminum-lined sachets at 25°C/60% RH maintains potency above 95% for 36 months; desiccant silica gel sachets are required when relative humidity exceeds 60% during packaging.